Merck (MRK) Ticks Higher Following Positive Odanacatib Phase III News
Tweet Send to a FriendGet Alerts MRK Hot Sheet
Price: $45.21 -1.7%
Overall Analyst Rating:
BUY (
Down)
Dividend Yield: 3.9%
Revenue Growth %: -99.9%
Overall Analyst Rating:
BUY (
Down)Dividend Yield: 3.9%
Revenue Growth %: -99.9%
Trade MRK Now!
Merck & Co. (NYSE: MRK) shares are ticking higher in late trading Wednesday, following positive news for its investigational cathepsin K (cat-K) inhibitor, odanacatib.
According to reports, odanacatib's Phase III is cleared for early cancellation by the DMC due to robust efficacy and a favorable benefit-risk profile.
Shares are about 3 percent higher late Wednesday.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
According to reports, odanacatib's Phase III is cleared for early cancellation by the DMC due to robust efficacy and a favorable benefit-risk profile.
Shares are about 3 percent higher late Wednesday.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Merck's (MRK) Suvorexant Faces Challenges at FDA
- Amarin's (AMRN) Vascepa Not in FDA Orange Book for April
- Clearwire (CLWR) Active as DISH Eyes Lightsquared Spectrum
Create E-mail Alert Related Categories
FDA, Insiders' Blog
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
